No description available.

京都大学 / 0048 / 新制・課程博士 / 博士(工学) / 甲第19750号 / 工博第4205号 / 新制||工||1649(附属図書館) / 32786 / 京都大学大学院工学研究科合成・生物化学専攻 / (主査)教授 濵地 格, 教授 森 泰生, 教授 杉野目 道紀 / 学位規則第4条第1項該当 / Doctor of Philosophy (Engineering) / Kyoto University / DFAM

Endothelial cells separate the bloodstream from the underlying tissue and play a crucial role in vascular homeostasis. They also form an important barrier for vascular drug delivery. This thesis contains preliminary studies targeted at understanding the mechanisms of binding and transport across endothelial cells cultured in vitro. Specifically, the first study investigates how the recombinant source of Factor IX (FIX), a blood coagulant protein used in the treatment of Hemophilia B, impacts surface ligand binding (FIX to its specific receptors) to bovine aortic endothelial cells (BAECs). Competitive binding experiments between 125I-FIX and FIX were undertaken to quantify the interaction of recombinant and transgenic FIX with BAECs and human collagen IV and determine if there was a measurable difference in binding affinity. Results indicate limited specific binding of 125I-FIX to BAECs and no binding to human collagen IV. Concrete conclusions were not drawn from this data due to technical issues during the experimental process. The second study investigates insulin-like growth factor-I (IGF-I) transport across both BAEC and MAC-T cells, a mammary epithelial cell line, cultured on tissue culture inserts. IGF-I is a circulatory growth factor implicated in the regulation of cell division and tissue proliferation. Competitive binding experiments between 125I-IGF-I and unlabeled protein (IGF-I, Y60L-IGF-I, a mutant of IGF-I, and IGF Binding Protein-3 (IGFBP-3)) were undertaken to quantify the binding and transport of IGF-I under various experimental conditions. Results confirmed earlier work from the Williams' laboratory indicating that 125I-IGF-I transport was enhanced by incubation with its non-receptor-binding analog, Y60L-IGF-I, but cell surface associated 125I-IGF-I was decreased by its presence. Other studies were undertaken but conclusive results could not be drawn. / Master of Science

Es wird allgemein angenommen, dass Proteine exponentiell degradiert werden. Das bedeutet, dass neu synthetisierte als auch alte Proteine mit gleicher Wahrscheinlichkeit degradiert werden. Es tauchen jedoch immer mehr Hinweise dafür auf, dass das nicht immer der Fall sein muss. Um diese Fragestellung systematisch anzugehen, haben wir eine Methode zur metabolischen Pulsmarkierung mit der nichtkanonischen Aminosäure Azidohomoalanine (AHA) entwickelt. AHA ermöglicht die Anreicherung von neu synthetisierten Proteinen direkt nach einem Puls oder nach einer „chase“ (Nachverfolgung) Periode in AHA freiem Medium. Wir kombinierten diese Methode mit SILAC und Shotgun Proteomik um zu quantifizieren wieviel Protein nach verschiedenen chase-Perioden übrig bleibt. Damit konnten wir Degradationsprofile für tausende von Proteinen erstellen. Unsere Daten zeigen, dass mehr als 10 % der Proteine nicht exponentiell degradiert werden (NED). Diese Proteine werden mit fortschreitendem Alter ausschließlich stabiler. Proteasomale Degradation von überschüssigen Proteinkomplexuntereinheiten scheint einen Großteil der NEDs zu erklären. Beim Vergleich zwischen murinen und humanen Zellen stellte sich heraus, dass NED teilweise konserviert ist. Das liegt scheinbar daran, dass diese Zellen trotz unterschiedlichem Ursprungs einheitlich bestimmte Untereinheiten überproduzieren. Da überschüssige NED Proteine bereits unter Standardbedingungen degradiert werden, nahmen wir an, dass die zusätzliche Überproduktion eines NED Proteins seine Level im stationären Zustand nicht verändern sollte. Um dies zu zeigen, quantifizierten wir Degradationskinetiken von Proteinen einer aneuploidenZelllinie. Wir fanden, dass NED Proteine, die auf trisomischen Chromosomen codiert sind, nicht in gleichem Maße ihr stationäres Level steigerten wie exponentiell degradierte Proteine. In Übereinstimmung mit unserer Hypothese verzeichneten wir stattdessen eine Zunahme der anfänglichen Degradationsraten dieser NED Proteine. / Proteins are thought to be degraded exponentially. That means that newly synthesized proteins have the same probability to be degraded as old proteins. However, evidence has accumulated showing that this is not true in all cases. To analyze this more systematically, we developed a method employing metabolic pulse-labeling by the non-canonical amino acid azidohomoalanine (AHA). AHA enables enrichment of newly synthesized proteins directly after pulse or after chase in AHA-free medium. We used SILAC and shotgun proteomics to quantify how much protein remains after different lengths of chase to create degradation profiles for thousands of proteins. Importantly, these degradation profiles allowed us to detect changes in degradation kinetics as the proteins age. We found that more than 10 % of proteins are non-exponentially degraded (NED). These protein are exclusively stabilized by age. Proteasomal degradation of excess protein complex subunits seems to explain a large fraction of NED. Comparing NED in mouse and human cells, we found that NED is at least partially conserved, seemingly due to cells consistently making too much of certain subunits. These overproduced subunits are on average shorter and more structured than the exponentially degraded proteins within the same complex. Finally, since excess NED proteins are degraded during baseline conditions, we hypothesized that making more of a NED protein would not increase its steady state levels. We employed an aneuploidy cell model and found that indeed NED proteins encoded on trisomic chromosomes did not increase in steady state levels to the same extent as exponentially degraded proteins. Instead, we recorded an increase in initial degradation of these proteins. In summary, we present a method for global pule-chase experiments allowing the detection of age-dependent protein degradation with possible implications for the understanding of aneuploidy and cancer.